2024. Drug Repurposing of Loratadine as a DNMT1 Inhibitor: Comparative Evaluation with Cisplatin in Patient-Derived Oral Squamous Cell Carcinoma Cells. Precision Medicine Communications. 4, 2 (Dec. 2024), 125–137. DOI:https://doi.org/10.55627/pmc.004.02.1083.